At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating ...

In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and Exposition which assessed a triplet nonchemotherapy regimen in older and medically unfit patients with ...

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL.

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

At the 2025 ASH Annual Meeting and Exposition, researchers presented new findings that may meaningfully affect how patients ...

Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), ...

Early ctDNA clearance, combined with complete response on PET-CT, correlates with prolonged progression-free survival. ctDNA testing is minimally invasive and can be conducted repeatedly, offering a ...

Matthew S. McKinney, MD, reflects on his first experience of treating a patient with diffuse large B-cell lymphoma (DLBCL) as a new attending at Duke University. The patient, a woman with multiple ...

BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...

Suchitra Sundaram, MD, emphasizes the significant disparities in the treatment and outcomes of patients with diffuse large B-cell lymphoma (DLBCL), which arise from a complex interaction of factors ...